1. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, Yuen K, Lee J, Gianoutsos P, Olver IN, Zalcberg J, Ball D, Bull C, Fox R (1987) Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 5: 1574
2. Bishop JF, Kefford R, Raghavan D, Zalcberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K, Zimet A (1990) Etoposide, carboplatin, cyclophosphamide and vincristine (ECCO) in previously untreated patients with small-cell lung cancer. Cancer Chemother Pharmacol 25: 367
3. Blackstein ME, Eisenhauer E, Wierzbicki R (1987) Phase II study of epirubicin in untreated patients with extensive small cell lung cancer. Proceedings, 4th European Conference on Clinical Oncology and Cancer Nursing, Madrid, November 1?4, p 22
4. Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G (1986) Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261
5. Campora E, Vinci P, Vischi M, Sertoli MR, Nobile MT, Feletti R, Ganzina F, Rosso R (1983) A phase II study of 4-epidoxorubicin. Chemoterapia 2: 226